Krystal Biotech Inc. trades under ticker KRYS on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US5011471027, CUSIP 501147102.
About the Company
Krystal Biotech Inc. is a biotechnology company primarily focused on developing and commercializing gene therapy products for patients with rare dermatological conditions. Its innovative platform harnesses gene delivery technology to address unmet medical needs by developing a pipeline of products aimed at treating genetic skin diseases. Krystal Biotech’s key asset is its proprietary STAR-D platform, which allows for the non-viral delivery of therapeutic genes directly into the skin. This platform exemplifies the company's commitment to deploying cutting-edge science to improve patient outcomes. The company primarily impacts the healthcare and biotechnology sectors, seeking to revolutionize treatments for genetic disorders. Incorporated in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a significant role in advancing therapeutic options within the niche market of dermatological diseases, thereby positioning itself as a transformative player in gene therapy and medical research.